KR20240021749A - 만성 신장병의 고양이의 치료 방법 - Google Patents

만성 신장병의 고양이의 치료 방법 Download PDF

Info

Publication number
KR20240021749A
KR20240021749A KR1020237035492A KR20237035492A KR20240021749A KR 20240021749 A KR20240021749 A KR 20240021749A KR 1020237035492 A KR1020237035492 A KR 1020237035492A KR 20237035492 A KR20237035492 A KR 20237035492A KR 20240021749 A KR20240021749 A KR 20240021749A
Authority
KR
South Korea
Prior art keywords
kidney disease
stage
cats
chronic kidney
bps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035492A
Other languages
English (en)
Korean (ko)
Inventor
타쿠미 마츠우라
하지무 쿠루마타니
Original Assignee
도레이 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도레이 카부시키가이샤 filed Critical 도레이 카부시키가이샤
Publication of KR20240021749A publication Critical patent/KR20240021749A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237035492A 2021-06-16 2022-06-15 만성 신장병의 고양이의 치료 방법 Pending KR20240021749A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021100475 2021-06-16
JPJP-P-2021-100475 2021-06-16
PCT/JP2022/023876 WO2022265031A1 (ja) 2021-06-16 2022-06-15 慢性腎臓病のネコの治療方法

Publications (1)

Publication Number Publication Date
KR20240021749A true KR20240021749A (ko) 2024-02-19

Family

ID=84527566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035492A Pending KR20240021749A (ko) 2021-06-16 2022-06-15 만성 신장병의 고양이의 치료 방법

Country Status (11)

Country Link
US (1) US12097177B2 (https=)
EP (1) EP4356908B1 (https=)
JP (1) JP7318818B2 (https=)
KR (1) KR20240021749A (https=)
CN (1) CN117396197A (https=)
AU (1) AU2022294552A1 (https=)
BR (1) BR112023023965A2 (https=)
CA (1) CA3217697A1 (https=)
ES (1) ES3054744T3 (https=)
MX (1) MX2023013545A (https=)
WO (1) WO2022265031A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025501556A (ja) * 2021-12-27 2025-01-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 慢性腎臓病を診断及び治療するための組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007668A1 (ja) 2005-07-08 2007-01-18 Toray Industries, Inc. 尿毒症改善のための治療剤および処置方法
WO2016031949A1 (ja) 2014-08-28 2016-03-03 東レ株式会社 慢性腎不全の治療薬

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58124778A (ja) 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPH075582B2 (ja) 1986-01-24 1995-01-25 東レ株式会社 ２，５，６，７−テトラノル−４，８−インタ−ｍ−フエニレンＰＧＩ▲下２▼誘導体
JPH0662599B2 (ja) 1987-10-16 1994-08-17 東レ株式会社 ２，５，６，７―テトラノル―４，８―インタ―ｍ―フェニレンＰＧＩ２誘導体ならびにその製造法および用途
CA2012081C (en) 1989-03-14 2000-08-29 Shigeki Itou 2,5,6,7-tetranor-4,8-inter-m-phenylene pgi 2 derivatives
WO1998041210A1 (en) 1997-03-14 1998-09-24 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
ES2272914T3 (es) 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
CA3164676A1 (en) 2019-12-23 2021-07-01 Toray Industries, Inc. Drug for preventing dialysis shift or renal death

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007668A1 (ja) 2005-07-08 2007-01-18 Toray Industries, Inc. 尿毒症改善のための治療剤および処置方法
WO2016031949A1 (ja) 2014-08-28 2016-03-03 東レ株式会社 慢性腎不全の治療薬

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease M. Takenaka J Vet Intern Med. 2018; 32:236-248.
Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M. Survival in cats with naturally occurring chronic kidney disease(2000-2002). J Vet Intern Med. 2008; 22(5): 1111-1117.
Brown CA, Elliott J, Schmiedt CW, Brown SA. Chronic Kidney Disease in Aged Cats: Clinical Features, Morphology, and Proposed Pathogeneses. Vet Pathol. 2016; 53(2): 309-326.
Cannon M. Diagnosis and investigation of chronic kidney disease in cats. In Practice. 2016; 38:2-9.
Chakrabarti S, Syme H, Brown C, Elliott J. Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction. Veterinary pathology. 2013; 50(1): 147-155.
Chakrabarti S, Syme HM, Elliott J. Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. J Vet Intern Med. 2012; 26(2): 275-281.
Finch NC, Syme HM, Elliott J. Development of an estimated glomerular filtration rate formula in cats. J Vet Intern Med. 2018; 32(6): 1970-1976.
Freeman LM, Lachaud MP, Matthews S, Rhodes L, Zollers B. Evaluation of Weight Loss Over Time in Cats with Chronic Kidney Disease. J Vet Intern Med. 2016; 30(5): 1661-1666.
Geddes RF, Elliott J, Syme HM. Relationship between plasma fibroblast growth factor-23 concentration and survival time in cats with chronic kidney disease. J Vet Intern Med. 2015; 29(6): 1494-1501.
Goto Y, Yamaguchi S, Tamura M, et al. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis. Prostaglandins Other Lipid Mediat. 2014; 112: 16-26.
Harley L, Langston C. Proteinuria in dogs and cats. Can Vet J. 2012; 53(6): 631-638.
Inc. BIV. FREEDOM OF INFORMATION SUMMARY ORIGINAL NEW ANIMAL DRUG APPLICATION NADA 141-501 SemintraTM (telmisartan oral solution) Oral Solution Cats For the control of systemic hypertension in cats. May 15,2018.
Inc. EU. FREEDOM OF INFORMATION SUMMARY ORIGINAL NEW ANIMAL DRUG APPLICATION NADA 141-536 EluraTMcapromorelin oral solution Cats For management of weight loss in cats with chronic kidney disease. October 16, 2020.
International Renal Interest Society. IRIS Treatment Recommendations for CKD. http://www.iris-kidney.com/education/staging_system.html. Accessed March 2021.
King JN, Gunn-Moore DA, Tasker S, Gleadhill A, Strehlau G. Benazepril in Renal Insufficiency in Cats Study G. Tolerability and efficacy of benazepril in cats with chronic kidney disease. J Vet Intern Med. 2006; 20(5): 1054-1064.
King JN, Tasker S, Gunn-Moore DA, Strehlau G, Group BS. Prognostic factors in cats with chronic kidney disease. J Vet Intern Med. 2007; 21(5): 906-916.
Langston CE, Cowgill LD, Spano JA. Applications and outcome of hemodialysis in cats: a review of 29 cases. J Vet Intern Med. 1997; 11(6): 348-355.
McLeland S, Cianciolo RE, Duncan C, Quimby J. A comparison of biochemical and histopathologic staging in cats with chronic kidney disease. Veterinary pathology. 2015; 52(3): 524-534.
Mizutani H, Koyama H, Watanabe T, et al. Evaluation of the clinical efficacy of benazepril in the treatment of chronic renal insufficiency in cats. J Vet Intern Med. 2006; 20(5): 1074-1079.
Polzin O, Ross. Ettinger SJ, Feldman CE (eds.) Textbook of Veterinary Internal Medicine, 6th. 2005; Vol 2: Chapter 260, 1756-1785.
Pouchelon JL, Atkins CE, Bussadori C, et al. Cardiovascular-renal axis disorders in the domestic dog and cat: a veterinary consensus statement. J Small Anim Pract. 2015;56(9): 537-552.
Sent U, Gossl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015; 29(6): 1479-1487.
Sparkes AH, Caney S, Chalhoub S, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3): 219-239.
Syme HM, Markwell PJ, Pfeiffer D, Elliott J. Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria. J Vet Intern Med. 2006; 20(3): 528-535.
Watanabe T, Mishina M. Effects of benazepril hydrochloride in cats with experimentally induced or spontaneously occurring chronic renal failure. J Vet Med Sci. 2007; 69(10): 1015-1023.
고양이 만성 신장병 치료약 라프로스의 사용 보고 카와즈 미쯔노부 SAC, 2019(Feb), No.193, 12-17.
고양이 만성 신장병(CKD)에 대한 베라프로스트나트륨 치료 업데이트 6예 핫토리 유키 SAC, No.188, 2017(Oct), 10-17.
고양이의 만성 신부전에 대한 베라프로스트나트륨의 치료 효과에 관한 검토 타케나카 마사히코, 타카시마 카즈아키, 쿠루마타니 모토, 이다 와타리 류, 야마네 요시히사 제 26회 동물 임상 의학회, 2005, 72-76.
고양이의 만성 신장병(CKD)에 대한 베라프로스트나트륨(BPS) 치료-계속 치료에 의해 확인된 것-이시다 타쿠오 WJVF 제 9회 대회 초록 집, 2018(Jul), 164-165.
고양이의 만성 신장병에 대한 베라프로스트나트륨(BPS)에 의한 치료 업데이트 사토 레에코, 타카시마 카즈아키, 타케나카 마사히코 J-VET, 2018(Mar), 372, 56-67.
고양이의 만성 신장병의 약품 요법∼ACEI, ARB, 베라프로스트∼치료약과 선택과 치료의 실제∼실제의 증례를 바탕으로∼이토 히로유키 제 16회 일본 수의 내과학 아카데미 학술 대회 초록집, 2019(Feb), vol. 2, 106-107.
신장 사이클링-만성 신장병에서의 약을 사용하는 방법-스테이지 25 ACE 저해약과 안지오텐신 2수 용체 길항약 미야카와 유우이치 MVM Vol. 30 No. 194 2021 1.
신장 사이클링-만성 신장병에서의 약을 사용하는 방법-스테이지 26 베라프로스트나트륨 미야카와 유우이치 MVM Vol. 30 No. 195 2021 3.
임상 수의사의 시점에서 생각하는 고양이 만성 신장병에 대한 약품 요법-QOL 개선 & 장기 생존을 기대할 수 있는 것은? 이토 히로유키 MVM Vol. 29 No.1922020.
임상 수의사의 시점에서 생각하는 고양이 만성 신장병에 대한 약품 요법－RA계 저해약과 베라프로스트나트륨을 중심으로-이토 히로유키 WJVF 제10회 대회 초록집, 2019(Jul), 275-279.
후지타 등 혈관 의학(2006), Vol.7, p.281.

Also Published As

Publication number Publication date
MX2023013545A (es) 2023-11-29
EP4356908A4 (en) 2024-10-23
US12097177B2 (en) 2024-09-24
WO2022265031A1 (ja) 2022-12-22
EP4356908A1 (en) 2024-04-24
CA3217697A1 (en) 2022-12-22
JP7318818B2 (ja) 2023-08-01
AU2022294552A1 (en) 2023-11-02
CN117396197A (zh) 2024-01-12
JPWO2022265031A1 (https=) 2022-12-22
US20240207218A1 (en) 2024-06-27
BR112023023965A2 (pt) 2024-01-30
EP4356908C0 (en) 2025-10-22
ES3054744T3 (en) 2026-02-05
EP4356908B1 (en) 2025-10-22
TW202317089A (zh) 2023-05-01

Similar Documents

Publication Publication Date Title
EP3439660B1 (en) Use of pimobendan for the reduction of heart size and the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
JP7402907B2 (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
KR20240021749A (ko) 만성 신장병의 고양이의 치료 방법
RS67322B1 (sr) Dapagliflozin za upotrebu u postupcima lečenja hronične bolesti bubrega
TWI867128B (zh) 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途
WO2020106738A1 (en) Use of higher doses of modified release huperzine formulations
KR20160091349A (ko) 부종없이 통증을 완화시키기 위한 고정된 용량의 복합제
WO2022251563A1 (en) Pediatric formulations of ferric citrate
CN116887843A (zh) 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法
RU2778313C2 (ru) Лекарственная композиция, включающая ингибитор sglt-2 и блокатор рецептора ангиотензина
Verma Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled
Bakris et al. Case study: the link between hypertension and diabetes
WO2013050339A1 (en) Pharmaceutical compositions of antihypertensives
CA3131445A1 (en) Pharmaceutical composition of prolyl hydroxylase inhibitor and preparation method therefor
SULLIVAN Colon Cancer Risk Rises With Low Vitamin D

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E14 Pre-grant third party observation filed

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E14-OPP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000